Christopher Cannon/LinkedIn
Oct 3, 2025, 11:50
Christopher Cannon on Evolocumab – Landmark Phase 3 Trial Shows Benefit in Those at High Risk of CV Events
Christopher Cannon, Cardiologist at Brigham and Women’s Hospital, Editor-in-Chief of Harvard Heart Letter, shared on LinkedIn:
”Late-breaking news!!!
PCSK9 inhibition with evolocumab shows benefit in those at high risk of CV events, (in addition to secondary prevention as shown in FOURIER)”
Read the full article here.
Article: Landmark Phase 3 Trial (Vesalius-CV) Meets Primary Endpoints in a Cardiovascular Primary Prevention Study of 12,000 Patients
Stay updated on the latest scientific breakthroughs with Hemostasis Today.
-
Apr 8, 2026, 07:32Giulia Simini: Acquired von Willebrand Syndrome and Coagulation Abnormalities in MPN-Associated Thrombocytosis
-
Apr 8, 2026, 07:14Julian Kyoung-Ryul Chun: Join the Discussion at EHRA 2026
-
Apr 8, 2026, 06:41Stephanie Diez de Sollano: Why Ehlers-Danlos Syndrome Deserves More Attention
-
Apr 7, 2026, 19:17Anand Padmanabhan: Persistence and Pathogenicity of Platelet Factor 4 Antibodies in VITT
-
Apr 7, 2026, 19:07Clara Meijs: Great Time Presenting Our Endometriosis Project at the AHA EPI Lifestyle Conference
-
Apr 7, 2026, 18:18Vivek Das: How Obesity, Type 2 Diabetes, and Dyslipidaemia Interact Across Multiple Cardiovascular Conditions
-
Apr 7, 2026, 17:44Augustina Isioma Ikusemoro: Quality Indicators for Red Blood Cells in Transfusion Medicine
-
Apr 7, 2026, 17:35Nikola Grubor: In Situ Pulmonary Arterial Thrombosis Mimicking CTEPH in Eisenmenger
-
Apr 7, 2026, 17:34Pooja Choradia: vWF Breakdown in Aortic Stenosis – Anaemia and Pulmonary Relevance